(Q40621694)

English

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1

scientific article published on September 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 (English)

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

1 reference

based on heuristic

inferred from title

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

John R. Mascola

5

object named as

John Mascola

1 reference

Europe PubMed Central

22 September 2017

Deborah L. Birx

17

object named as

Deborah L Birx

1 reference

Europe PubMed Central

22 September 2017

15

object named as

Merlin L Robb

1 reference

Europe PubMed Central

22 September 2017

1

object named as

Jerome H Kim

1 reference

Europe PubMed Central

22 September 2017

Victoria R Polonis

8

object named as

Victoria Polonis

1 reference

Europe PubMed Central

22 September 2017

Punnee Pitisuttithum

2

object named as

Punnee Pitisuttithum

1 reference

Europe PubMed Central

22 September 2017

Robert McLinden

9

object named as

Robert McLinden

1 reference

Europe PubMed Central

22 September 2017

Thippawan Chuenchitra

4

object named as

Thippawan Chuenchitra

1 reference

Europe PubMed Central

22 September 2017

author name string

Chirasak Kamboonruang

3

1 reference

Europe PubMed Central

22 September 2017

Anna Sambor

10

1 reference

Europe PubMed Central

22 September 2017

Benjaluck Phonrat

12

1 reference

Europe PubMed Central

22 September 2017

Kittipong Rungruengthanakit

13

1 reference

Europe PubMed Central

22 September 2017

Anne-Marie Duliege

14

1 reference

Europe PubMed Central

22 September 2017

John McNeil

16

1 reference

Europe PubMed Central

22 September 2017

Thai AIDS Vaccine Evaluation Group

18

1 reference

Europe PubMed Central

22 September 2017

John Mascola

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Sarah S. Frankel

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Mark S. DeSouza

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Victoria Polonis

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

Arthur E. Brown

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585211

26 March 2024

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2003

1 reference

Europe PubMed Central

22 September 2017

full work available at URL

http://www.liebertpub.com/doi/pdf/10.1089/088922203769232601

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

AIDS Research and Human Retroviruses

1 reference

Europe PubMed Central

22 September 2017

19

1 reference

Europe PubMed Central

22 September 2017

9

1 reference

Europe PubMed Central

22 September 2017

807-816

1 reference

Europe PubMed Central

22 September 2017

Global burden of the HIV pandemic

2

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Changes in sexual behavior and a decline in HIV infection among young men in Thailand.

3

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

4

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

5

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

7

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

8

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

10

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

11

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

12

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

13

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

14

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization

15

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

16

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines

17

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

20

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

HIV-1 nomenclature proposal.

21

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

23

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Wide distribution of two subtypes of HIV-1 in Thailand

24

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Genetic variants of HIV-1 in Thailand

25

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

29

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

30

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

31

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140

33

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120

34

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates

35

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

36

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

39

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

41

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

42

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1

46

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Public health. AIDS vaccine trial produces disappointment and confusion

47

1 reference

10.1089/088922203769232601

https://api.crossref.org/works/10.1089/088922203769232601

26 March 2024

Identifiers

10.1089/088922203769232601

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40621694&oldid=2111552468"